VERA250117C22500
- 23.90
- 0.000.00%
Vera Therapeutics Newsroom
Insiders At Vera Therapeutics Sold US$1.0m In Stock, Alluding To Potential Weakness
Vera Therapeutics Grants Stock Options And RSUs To Six New Employees
LifeSci Capital Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $70
Vera Therapeutics: Strategic Licensing and Promising Clinical Data Justify Buy Rating
Express News | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Evercore Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $75
Evercore ISI Sticks to Its Buy Rating for Vera Therapeutics (VERA)
What's Going On With Vera Therapeutics Stock?
Vera Therapeutics Shares Are Trading Lower. The Company Announced an Exclusive License Agreement With Stanford University for VT-109.
Vera Therapeutics Highlights Atacicept Progress at Conference
Vera Therapeutics Announced An Exclusive License Agreement With Stanford University For Fusion Protein Targeting BAFF And APRIL, Known As VT-109, With Therapeutic Potential Across The Spectrum Of B Cell-mediated Diseases For Undisclosed Upfront And...
Express News | Vera Therapeutics Inc - to Develop and Market Vt-109 With Undisclosed Payments
Press Release: Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor
Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Vera Therapeutics Insider Sold Shares Worth $753,680, According to a Recent SEC Filing
Vera Therapeutics (VERA) Receives a Buy From TD Cowen
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics (VERA) Gets a Buy From J.P. Morgan
Wells Fargo Initiates Vera Therapeutics(VERA.US) With Buy Rating, Announces Target Price $70